Articles tagged "HLA antibodies"

2022 American Transplant Congress
De Novo Donor-Specific Antibody Development with Mycophenolate versus Azathioprine in Lung Transplant Recipients
A. Prom¹, K. Walter², K. Gomez³, C. Doligalski¹, L. Lobo¹, R. Evans¹
¹UNC Health, Chapel Hill, NC, ²University of Michigan, Ann Arbor, MI, ³University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC
*Purpose: The effect of mycophenolate mofetil (MMF) or azathioprine (AZA) immunosuppression (ISN) regimens on de novo donor specific antibody (DSA) formation in lung transplant recipients…
2022 American Transplant Congress
Site-Directed Mutagenesis as a Tool to Investigate Immunogenicity of HLA Epitopes for Humoral Alloreactivity
C. H. Maguire¹, P. Crivello², A. Tambur¹
¹Northwestern University, Chicago, IL, ²University Hospital Essen, Essen, Germany
*Purpose: Molecular mismatch load (MML) analysis has been a proposed approach to assess donor/recipient compatibility in support of organ allocation algorithms. While conceptually appealing, MML…
2022 American Transplant Congress
Poor Outcomes in Patients with Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions
K. Wu¹, D. Schmidt¹, C. Lopez del Moral¹, Q. Zhang¹, F. Halleck¹, M. G. Naik¹, N. Lachmann², B. Rudolph³, K. Budde¹
¹Department of Nephrology, Charite Campus Mitte, Berlin, Germany, ²Institut für Transfusionsmedizin, Charite Virchow Klinikum, Berlin, Germany, ³Institut für Pathologie, Charite Campus Mitte, Berlin, Germany
*Purpose: Banff classification is an accepted diagnostic tool, but also used as a tool to define endpoints in clinical trials. There is a need to…
2022 American Transplant Congress
“ABO-Adjusted CPRA”: A Unified Metric for Immunologic Compatibility in Kidney Transplantation
L. Gragert¹, M. Kadatz², J. Alcorn³, D. Stewart³, D. Chang², J. Gill², R. Liwski⁴, H. Gebel⁵, E. Kransdorf⁶, J. Gill², J. Lan²
¹Tulane University, New Orleans, LA, ²University of British Columbia, Vancouver, BC, Canada, ³UNOS, Richmond, VA, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Emory University, Atlanta, GA, ⁶Cedars-Sinai, Beverly Hills, CA
*Purpose: Implementation of the kidney allocation system in 2014 greatly reduced access disparity due to HLA sensitization. To address persistent disparities among both candidate cPRA…
2022 American Transplant Congress
Bone Marrow Resident Long-Lived Plasma Cells as Source of Chronic Donor-Specific Antibodies
M. Muckenhuber, S. Pichler, A. M. Weijler, T. Wekerle
Dept. of General Surgery, Div. of Transplantation, Medical University of Vienna, Vienna, Austria
*Purpose: The importance of bone marrow resident plasma cells for long-lasting humoral immunity has been highlighted in several models for vaccination and infectious diseases. To…
2022 American Transplant Congress
Characterizing the Landscape of Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, K. Yu², R. M. Pfeiffer², A. Massie¹, J. Garonzik-Wang³, D. Segev¹, E. A. Engels²
¹Johns Hopkins University, Baltimore, MD, ²National Cancer Institute, Bethesda, MD, ³University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2022 American Transplant Congress
Outcomes of Highly-Sensitized, Virtual and Flow Cross-Match Negative Renal Transplant Recipients: A Retrospective Observational Study
A. Agrawal¹, B. Smith¹, M. Gandhi², C. Schinstock¹
¹Transplant Nephrology, Mayo Clinic, Rochester, MN, ²Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
*Purpose: Many highly-sensitized kidney transplant recipients are sensitized from prior transplants, which have been shown to limit graft survival more than pregnancy or blood transfusions.…
2022 American Transplant Congress
Prolonged Xeno-Kidney Graft Survival in Highly Allo-Sensitized Nonhuman Primate Using Triple-Knockout Donor Pigs with 7 Human Transgenes
M. Manook¹, D. Olaso¹, I. Anwar¹, J. Yoon¹, M. Song¹, A. B. Farris², K. Stiede³, K. Hall³, M. Youd³, S. Knechtle¹, J. Kwun¹
¹Surgery, Duke Transplant Center, Durham, NC, ²Pathology, Emory University, Atlanta, GA, ³eGenesis Inc, Cambridge, MA
*Purpose: We have previously shown using porcine kidneys from genetically modified knockout alpha 1,3-galactosyltransferase (GGTA1KO) and human decay accelerating factor transgenic (CD55Tg) pigs that compared…
2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²SSM Health Saint Louis University Hospital, Saint Louis, MO, ³Barnes-Jewish Hospital, Edwardsville, IL, ⁴Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Barnes-Jewish Hospital, St. Louis, MO, ⁸Washington University, St Louis, MO, ⁹Transplant, Washington University, St. Louis, MO
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…
2022 American Transplant Congress
HLA DSA May Not Be Detected in Many Solid Organ Recipients
J. C. Quon¹, R. M. Lestz², J. Menteer², N. Fotiadis², L. A. Baxter-Lowe²
¹Keck School of Medicine, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
*Purpose: Clinically significant HLA antibodies may not be detected if their unique HLA epitopes are not represented in the single antigen reagents that are routinely…